Document Type : Original Article
Authors
Neurology Department, Faculty of Medicine, Al-Azhar University
Abstract
Keywords
Main Subjects
Evaluation of Cerebral Arteriovenous Malformations (AVMs): Postoperative Endovascular Intervention Clinical and Radiological Outcome in Al-Azhar Hospitals
Ahmed Nabil Hussein, Khaled Mohamed Sobh and Mahmoud Galal Ahmed
Neurology Department, Faculty of Medicine, Al-Azhar University
Corresponding author: Ahmed Nabil Hussein; Email: Elagouz22@gmail.com; Phone: 01554119060
ABSTRACT
Background: Arteriovenous malformation (AVMs) is a collection of dysplsatic plexiform vessels that is supplied by one or more arterial feeders and drained by one or more venous channels. AVMs may have a pure plexiform nidus or contain a mixed plexiform fistulous nidus.
Objective: To evaluate cerebral AVMs postoperative endovascular embolization by intervention, clinical and radiological outcome in a sample of Egyptian patients.
Patients and Methods: This was a retrospective study of all consecutive patients who had underwent endovascular embolization for cerebral AVMs between December 2006 up to April 2021.One hundred sixty-nine (169) patients (91 female and 78 males) with cerebral arteriovenous malformations were treated by embolization at the Neurointervention Unit at Al-Hussein Hospital University
Results: The mean age in our study was 32.85 years with a range of 6-80 years, and the standard deviation was 14.875 years . The sex distribution showed slight higher incidence in females (53.8%) than in males (46.2%), and twenty eight patients (16.6%) were with family history of cerebral AVMs. The most common presnetation was intracranial hemorrhage (prsented as weakness), seizure came second, and headache came third Other neurological deficits (focal deficits , learning disability and cognitive impairment) were due to AVM itself. were significant difference in nidus diameter, and the Spetzler and Martin grading of the cerebral AVMs after embolization in comparison to before embolization.
Conclusion: The endovascular treatment of the cerebral AVMs was safe, efficient and achieved high rates of total and near total occlusion.
Keywords: Cerebral Arteriovenous Malformations (AVM), and Postoperative Endovascular Intervention Clinical, Radiological Outcome.
INTRODUCTION
Arteriovenous malformation (AVMs) is a collection of dysplsatic plexiform vessels that is supplied by one or more arterial feeders and drained by one or more venous channels. AVMs may have a pure plexiform nidus or contain a mixed plexiform fistulous nidus (Gross and Sacho, 2021).
The AVMs detection rate is 1.1-1.2/100,000 people/year and the incidence of AVM hemorrhage is 0.42/100,000 persons/year (Nitzan-Hirsh and Golan, 2020).
The vast majority of all AVMs are located in the cerebral hemispheres (85% supratentorial) large majority located superficially, whereas only 10% are located deep in the cerebral hemisphere, including the basal ganglia, ventricles and corpus callosum. Only 15% occur in the posterior fossa, cerebellar hemisphere is a more common site than brainstem (Ganaw et al., 2019).
Patients with AVMs present with hemorrhage in 50% of the cases which is considered the most common presentation; seizures in 30%; headaches in 10% and neurological deficit in 10%, any one of these symptoms may occur alone. The pathophysiological mechanisms may lead to more than one mode of presentation (Williams et al., 2019).
Until recently, the gold standard for diagnosing AVMs is conventional angiography (Pezeshkpour et al., (2020).
Modern treatment of cerebral AVMs comprise the following interventions alone or in combination: microsurgical excision, stereotactic radiosurgery, and endovascular embolization (Zuurbier and Salman, 2019).
Endovascular embolization can be used for a curative embolization, nidus reduction before surgery or radiosurgery and palliative embolization. The goal of curative embolization is the complete and permanent obliteration of the AVMs nidus with the restoration of the normal arterial blood flow and the preservation of venous drainage (Al-Mufti et al., 2021).
The most commonly used embolic agent is the rapidly polymerizing liquid embolic agent n-Butyl Cyano-Acrylate (nBCA). The use of nBCA for brain AVMs requires experience and skill, because of the intra-nidal flow and polymerization of nBCA are both quick and largely unpredictable (Hill et al., 2018).
After the introduction of the Onyx liquid embolic system (EV3, Irvine, CA) which is less adhesive, more slowly polymerizing and accordingly much more advantageous than nBCA, nBCA was largely replaced as an agent for AVMs embolization (Al-Mufti et al., 2021).
The present work aimd to evaluate cerebral AVMs postoperative endovascular embolization by intervention, clinical and radiological outcome in a sample of Egyptian patients.
PATIENTS AND METHODS
This was a retrospective review of all consecutive patients who had underwent endovascular embolization for cerebral AVMs between December 2006 up to april 2021. One hundred sixty-nine (169) patients (91 females and 78 males) with cerebral arteriovenous malformations were treated by embolization at the Neurointervention Unit in Al-Hussein Hospitals Al-Azhar University.:
Inclusion criteria: All patients presented by cerebral AVMs and subjected to Al-Azhar Neurointervention Units,ie. since December 2006 up to April 2021 (ruptured or unruptured AVM) either symptomatic or discovered accidently, with high bleeding risk due to small size (< 3 cm), deep venous drainage, and/or associated aneurysm. Patients with recent intracranial hemorrhage were postponded for at least 2 weeks (hematomas may interfere with good angiographic assessment).
Preprocedural assessment:
- Complete medical history.
- Complete general and neurological examinations.
- Laboratory investigations with stressing on:
- Radiological investigations:
Follow up by IA-DSA and repeated scoring on Spetzler-Martin AVMS grading system were done within 6 months after embolization.
Modified Rankin scale was applied for patients presented with weakness before embolization and follow up after 6 months. Less than 3 indicated improvement and 3 or more indicated disability.
0 = No symptoms at all.
1 = No significant disability despite symptoms, able to carry out all usual duties and activities.
2= Slight disability, unable to carry out all previous activities, but able to look after own affairs without assistance.
3= Moderate disability, requiring some help, but able to walk without assistance.
4= Moderat to severe disability, unable to walk without assistance, and unable to attend to on bodily needs without assistance.
5= Severe disability, bedridden, incontinent, requiring constant nursing care and attention.
Statistical analysis
Qualitative data were presented as numbers and percentages and tested with Monte-Carlo method were performed. Quantitative data were presented as mean ± standard deviation and the differences in quantitative data between groups were tested with t-test or Wilcoxon Signed Ranks Test .
P value
Statistical Package for the Social Sciences (SPSS) v 26 was used
RESULTS
One hundred sixty-nine patients with cerebral arteriovenous malformations fulfilled the criteria of inclusion in this study were embolized. The mean age in our study was 32.85 years with range of 6-80 years and the standard deviation was 14.875 years. The sex distribution showed slight higher incidence in females (53.8%) than in males (46). (table1).
Table (1):Age and sex distribution.
Factors |
Frequency (n =169) |
Percentage |
Gender |
|
|
Males |
78 |
46.2 |
Females |
91 |
53.8 |
Age |
|
|
Mean ± SD |
32.85 ± 14.875 |
Mean ± SD |
Max. – Min. |
6 – 80 |
Max. – Min. |
There was twenty-eight patients (16.6%) with family history of cerebral AVMs, there was forty-eight patients (28.4%) with hypertension of cerebral AVMs, there was forty-one (24.3%) with diabetes mellitus of cerebral AVMs, there was fifty-seven patient (33.7%) with smoking of cerebral AVMs (Table 2).
Table (2): Risk factors among the study.
Risk factors |
Frequency (n =169) |
Percentage |
HTN |
|
|
No |
121 |
71.6 |
Yes |
48 |
28.4 |
DM |
|
|
No |
128 |
75.7 |
Yes |
41 |
24.3 |
Smoking |
|
|
No |
112 |
66.3 |
Smoker |
57 |
33.7 |
Family history |
|
|
No |
141 |
83.4 |
Yes |
28 |
16.6 |
In our study, 75 patients (44.38%) were presented with focal neurological deficit due to Hemorrhage, 42 patients (24.85%) with fits, 36 patients (21.30%) with headache and 16 patients with other neurological deficit (focal deficits, learning disability and cognitive impairment) due to AVM itself (9.47%) (Table 3).
Table (3): Clinical presentation of cerebral AVMs in the study.
Factor |
Patients |
Percentage |
Presentation |
|
|
Neurological deficit due to Hemorrhage |
75 |
44.38 |
Fits |
42 |
24.85 |
Headache |
36 |
21.30 |
Others neurological deficit due to AVMs itself |
16 |
9.47 |
There was a significant difference in nidus diameter in all patients after embolization in comparison to before embolization (p = 0.000) (Table 4).
Table (4): Nidus diameter before and after embolization in our study by cm.
Nidus diameter |
Before embolization |
After embolization |
p value |
Mean ± SD |
3.96 ± 0.81 |
1.39 ± 0.7 |
0.01 |
SD: standard deviation. Paired p-test was used to compare between the repeated continuous data.
Nidus diameter and number of nidus less than 3 cm significantly reduced after the intervention compared to baseline values (P < 0.0001)
Table (5): Number of patient with AVMs nidus more than 8cm less than 3cm before and after embolization.
Groups Nidus diameter |
Before |
After |
P value |
||
Number |
Percentage |
Number |
Percentage |
||
≤ 3 cm |
20 |
11.8 |
158 |
93.5 |
0.00 |
> 3 cm |
149 |
88.2 |
11 |
6.5 |
McNemar Test was used to compare between the repeated qualitative data.
. There was significant difference in Spetzler and Martin grading system before and after embolization (p = 0.001). spetzler and Martin score of the cerebral AVMs was significantly improved after 6 months of the intervention compared to the initial grading score (P < 0.0001). (Table 6).
Table (6): Spetzler and Martin grading of the cerebral AVMs before and 6-month follow up after embolization.
Groups Spetzler and Martin grading |
Before embolization |
After embolization |
P |
||
No |
% |
No |
% |
||
Grade I |
0 |
0 |
0 |
0 |
<0.01 |
Grade II |
24 |
14.2 |
149 |
88.2 |
|
Grade III |
93 |
55 |
0 |
0 |
|
Grade IV |
35 |
20.7 |
0 |
0 |
|
Grade V |
17 |
10 |
0 |
0 |
|
Complete occlusion |
0 |
0 |
20 |
11.8 |
|
Total |
169 |
100 |
169 |
100 |
|
Wilcoxon Signed Ranks Test was used to compare between the repeated qualitative ordinal data.
Modified Rankin scale score for patients presented with side weakness was significantly improved after 6 months of the intervention compared to the initial grading score (Table7).
Table (7): Modified Rankin scale before and 6-month follow up after embolization.
Groups Modified Rankin scale |
Before embolization |
After embolization |
P value |
||
No |
% |
No |
% |
<0.01 |
|
Grade I |
0 |
0 |
15 |
50 |
|
Grade II |
0 |
0 |
8 |
25 |
|
Grade III |
16 |
50 |
12 |
25 |
|
Grade IV |
22 |
50 |
3 |
0 |
|
Grade V |
0 |
0 |
0 |
0 |
|
Total |
38 |
100 |
38 |
100 |
Wilcoxon Signed Ranks Test was used to compare between the repeated qualitative ordinal data.
As regards the final outcome, 20 patients (11.83%) showed complete occlusion of the nidus and 149 patients (88.17%) had Suitable for radiosurgery.(Table8).
(Table(8): Final outcome in our study
Outcome |
No |
% |
Complete occlusion |
20 |
11.83 |
Suitable for radiosurgery |
149 |
88.17 |
Total |
169 |
100 |
DISCUSSION
The mean age of the patients in our study was 32.85 years with range of 6-80 years and the standard deviation was 14.875 years. The age distribution recorded incidence peaks in the 3rd and 4th decade as the mean age of the patients was 32.85 years which was supported by Krithika and Sumi (2020) whoreported that the mean age at diagnosis is 31.2 years.
The sex distribution showed slight higher incidence in females (53.8%) than in males (46.2%) which agreed with the study done by Ganaw(2019) who reported that higher incidence in females (57.8%) than in males (42.2%) .
This did not goe with the results which reported that 60.67% were males and 39.32% were females Cai et al.(2020), also with He et al.(2018).
Hypertension, diabetes mellitus, smoking, and family history were risk factors. Smoking was most significantly associated risk factor, present in 33.7 % of patients, followed by hypertension in 28.4 %.that was controversy to Bokhari and Bokhari (2020) who presented smoking as the most significant association followed by hypertension, due to the which could be low incidence of smoking in Egyptian females which constituted 53.8% of our patients.
This was in agreement with the studies conducted by Deng et al (2020) where they found smoking as number one risk factor in 58.8% of cases, followed by hypercholesterolemia 21%, then hypertension comes in 19.8% of cases, diabetes with 6.2%, and family history is the last factor which was present in only 1.1% .
Regarding the presentation of the cerebral AVMs in our study, presented with neurological deficit due to hemorrhage, 24.85% with fits, 21.30% with headache and other neurological deficit (focal deficits, learning disability and cognitive impairment) due to AVM itself 9.47% which was going strongly with Wang et al.(2020) who showed that 48% presented with hemorrhage, 21% with seizure, 16% with headache and 10% with no symptoms.
A systematic literature review by Abecassis and colleagues(2014) found that between 36% to 38% of new cases presented as a first-time hemorrhagwhich runsin the same line with our results. Also, Bokhari and Bokhari (2020) reported that seizure is second presenting disorder in 15 to 40% of patients. Also
These has controversy to the study done by De Sousa et al. (2020) that showed the commonest clinical presentation was unspecific headache in 46% of cases, followed by epilepsy in 23% of cases, while only 20% came with intracerebral hemorrhage as first presentation and 11% accidentally discovered.
Chen et al. (2019) proved that headache was the second common presentation following the intracranial hemorrhage, and seizure was the third common presentation accounting for about 17.3% which did not go with our study.
Regarding AVMs characteristics as side, site, size, venous drainage and dural supply, our study showed that the AVMs were located in the right hemisphere in 55.62% and in the left hemisphere in 44.38%.The location of the AVMs in order of decreasing frequency was parieto-occipital 29.6%, parietal 26.6%, tempro-parietal 14.8%, temporal 14.8%, frontal 8.3% and cerebellar hemisphere 5.9%. These results in agreement with AA, et al.(2014).
Our study showed that Nidus diameter before embolization of the AVMs was < 3 cm in 11.83%, 3 – 6 cm in 79.88% and > 6 cm in 8.28%. The venous drainage of the AVMs was multiple in 30.76%, single in 69.23%. The number of feeders in our study was multiple in 41.42%, single in 58.57%. The dural supply of the AVMs was positive in 20.1% and negative in 79.9%. These results agreed to some extent and differed in some characteristics, with the study done by Dagli et al. (2021).
commonly used grading scale for brain AVMs was Spetzler-Martin Grade (SMG) scale, which was a composite score of nidus size (3 cm, 3-6 cm, 6 cm; 1-3 points), eloquence of adjacent brain (one point if located; brainstem, thalamus, hypothalamus, cerebellar peduncles or sensorimotor, language or primary visual cortex), and presence of deep venous drainage (one point if any or all drainage was through deep veins, such as internal cerebral veins, basal veins or precentral cerebellar veins Bokhari and Bokhari (2020).
The Spetzler and Martin grading of the cerebral AVMs before embolization was grade I in 0 patient (0%), grade II in 14.2%, grade III in 55%, grade IV in 20.7% and grade V in 10%.
This was in agreement with AA, et al.(2014).who found that 0 patients were grade I (0%), 15 patients were grade III (60%) and 5 patients were grade IV (20%). this disagreeed to some extent with Narsinh et al.(2021) who found in their series that 25 patients were grade I or II, 10 patients were grade III and 12 patients were grade IV or V.
In this work, 360 sessions of injection were done to all patients. The majority of patients received 1-4 sessions. The nidus diameter reduction after embolization was complete reduction (total occlusion) in 11.8% and partial reduction 88.2%.
There was a marked reduction in nidus diameter after embolizationn which 6.5% had nidus diameter > 3 cm, while 81.6% had nidus diameter ≤ 3 cm. There was a significant difference in nidus diameter in all patients after embolization in comparison to before embolization.
Total occlusion occurred in 11.8%, while the remaining 88.2% had cerebral AVMs with grade II according to the Spetzler and Martin classification of the cerebral AVMs There was a significant difference in Spetzler and Martin grading system before and after embolization.
Regarding the modified Rankin scale before embolization and 6-months follow up after embolization for patients presented with weakness (less than 3 indicates improvement and 3 or more indicates disabled). All patients were disabled before embolization with grade III weakness or more on the MRS and only 25% were disabled after embolization with grade III weakness on the MRS. Modified Rankin scale score for patients presented with side weakness was significantly improved after 6 months of the intervention compared to the initial grading score .
Our results were near to that of Lv et al. (2011) found in their series that clinically significant deficit was detected in 5% of the patients and 4.1% were disabled, and De Sousa et al.(2020) who observed that 10% of patients had modified Rankin scale 3 to 5 after AVMs embolization. In contrast these results were inconsistent with Wang et al.(2020) who found 2% had persistent neurological deficit (modified Rankin scale 3 to 5, and Narsinh et al.(2021) who found that 14% of patients were disabled after AVMs embolization,
Regarding the outcome of epilepsy after 6 months, we found that 76.2% had epilepsy and controlled, while in the 23.8%, the fits became infrequent. This could be explained by presence of edema and inflammation surrounding the nidus.
Well controlled seizure, if the patient had no seizures was in the last 3 months and infrequent seizureif the patient had one to six seizures per year. Regarding the outcome of headache after 6 months, we found that 89% improved and 11% did not improve. These results ware in agreement with AA, S, et al.(2014). showed that 83.3% improved and 16.7% was not improved.
As regards the final outcome, 11.83% showed complete occlusion of the nidus and 88.17% had partial reduction of the nidus and were candidate for radiosurgery.
There results were in agreement with AA, S, et al.(2014). Who showed that 20% with complete occlusion of the nidus and 80% had partial reduction of the nidus, and were candidate for radiosurgery.
CONCLUSION
The endovascular treatment of the cerebral AVMs was safe, efficient and can achieve high rates of total and near total occlusion. indicated that curative embolization of AVMs can achieve high rates of total and near total occlusion with acceptable complications.
REFERENCES
AA, S., MA, A., KM, S. and TSS, E. S. (2014): Endovascular embolization of cerebral arteriovenous malformations. ZagazigUniversity Medical Journal, 20(1): 1-7.
Abecassis, I. J., Xu, D. S., Batjer, H. H. and Bendok, B. R. (2014): Natural history of brain arteriovenous malformations: a systematic review. Neurosurgical focus, 37(3), E7.
Al-Mufti, F., Stein, A., Damodara, N., Joseph-Senatus, G., Nuoman, R., Nuoaman, H. and Gandhi, C. D. (2021):Decision-making for patients with cerebral arteriovenous malformations. Cardiology in Review, 29(1), 10-14.
Bokhari, S. R. A., Inayat, F., Bokhari, M. R., & Mansoor, A. (2020): Primary renal lymphoma: a comprehensive review of the pathophysiology, clinical presentation, imaging features, management and prognosis. BMJ Case Reports CP, 13(6), e235076.
Chen, C. J., Shabo, L. M., Ding, D., Ironside, N., Kano, H., Mathieu, D.and Foundation, I. R. R. (2019): Seizure presentation in patients with brain arteriovenous malformations treated with stereotactic radiosurgery: a multicenter study. World neurosurgery; 126: e634-e640.
Dagli, O., Bostanci, E., Emmez, O. H., Ekinci, F. and Celtikci, E. (2021): A Statistical Analysis of the Effect of Different Embolization Materials on Gamma Knife Arteriovenous Malformation Dose Distributions. 24(2), 98.
Deng, Z., Chen, Y., Ma, L., Li, R., Wang, S., Zhang, D. and Zhao, J. (2020): Long-term outcomes and prognostic predictors of 111 pediatric hemorrhagic cerebral arteriovenous malformations after microsurgical resection: a single-center experience. Neurosurgical Review, 1-9.
De Sousa, J. M. B., Iosif, C., Sganzerla, L. Z., Rafie, A. N., Borodetsky, V., Rouchaud, A.,... and Mounayer, C. (2020): Selection of Patients for Treatment of Brain Arteriovenous Malformations by the Transvenous Approach: Relationship with Venous Anatomy and Risk of Hemorrhagic Complications. American Journal of Neuroradiology, 41(12): 2311-2316.
Ganaw, A. E. A., Tharayil, A. M., Ehfeda, M., Alfared, M. H., Zeeshan, Q., Ahmed, S. M.,... and Shallik, N. (2019): Cerebral Arteriovenous Malformations (cAVMs): What Is New?. Vascular Malformations of the Central Nervous System). 2(2): 456-457
Gross, W. L., and Sacho, R. H. (2021): Intracranial Vascular Procedures. Anesthesiology Clinics, 39(1): 1-18.
He, Y., Bai, W., Li, T., Hui, F. K., He, Y. and Xu, B. (2018): Curative transvenous embolization for ruptured brain arteriovenous malformations: a single-center experience from China. World neurosurgery, 116, e421-e428.
Hill, H., Chick, J. F. B., Hage, A., and Srinivasa, R. N. (2018): N-butyl cyanoacrylate embolotherapy: techniques, complications, and management. Diagnostic and Interventional Radiology, 24(2), 98-99.
Krithika, S., and Sumi, S. (2020): Neurovascular inflammation in the pathogenesis of brain arteriovenous malformations. Journal of Cellular Physiology, 236(7):4841-56.
Lv X, Wu Z, Jiang C, Li Y, Yang X and Zhang Y (2011): Complication risk of endovascular embolization for cerebral arteriovenous malformation. Eur J Radiol; 80: 776-779.
Narsinh, K. H., Gautam, A., Baker, A., Cooke, D. L. and Dowd, C. F. (2021): Vascular anomalies: Classification and management. In Handbook of Clinical Neurology (Vol. 176, pp. 345-360).
Nitzan-Hirsh, A. A. and Golan, S. (2020): Advocating Intraluminal Radiation Therapy in Cerebral Arteriovenous Malformation Treatment. Vascular Malformations of the Central Nervous System, 35(8): 1371-1379
Pezeshkpour, P., Dmytriw, A. A., Phan, K., Shroff, M. M., Dirks, P., Kulkarni, A. V., and Muthusami, P. (2020): Treatment strategies and related outcomes for brain arteriovenous malformations in children: a systematic review and meta-analysis. American Journal of Roentgenology, 215(2): 472-487.
Wang, A., Mandigo, G. K., Feldstein, N. A., Sisti, M. B., Connolly, E. S., Solomon, R. A., ... and Meyers, P. M. (2020): Curative treatment for low-grade arteriovenous malformations. Journal of neurointerventional surgery, 12(1): 48-54.
Williams, V., Jayashree, M., Bansal, A., Baranwal, A., Nallasamy, K., Singhi, S. C.,... and Gupta, S. K. (2019): Spontaneous intracranial haemorrhage in children—intensive care needs and predictors of in-hospital mortality: a 10-year single-centre experience. Child's Nervous System, 35(8): 1371-1379.
Zuurbier, S. M., and Salman, R. A. S. (2019): Interventions for treating brain arteriovenous malformations in adults. Cochrane Database of Systematic, 12(1): 48-54.
التقييم الاكلينيكي و الاشعاعي من خلال الأشعة لعلاج حالات انصمام التشوهات الشريانية الوريدية المخية ما بعد التدخل بالقساطر متناهية الصغر وحقن المواد المجلطة في مستشفيات جامعة الأزهر
أحمد نبيل حسين محمد ، خالد محمد صبح ، محمود جلال أحمد
قسم الأمراض العصبيه- كليه طب- جامعه الأزهر
البريد:elagouz22@gmail.com
الهاتف :01554119060
خلفية البحث: دراسه حشديه تراجعيه لجميع المرضى الذين خضعوا للعلاج بالقسطره التداخليه والذين يعانون من تشوه الشرياني الوريدي الدماغي في الفترة من ديسمبر 2006 حتى أبريل 2021 حيث تم علاج مائة تسعة وستين (169) مريضًا (91 إناثًا و 78 ذكورا ) كانوا يعانون من التشوهات الشريانية الوريدية الدماغية و تم علاجهم عن طريق القسطره التداخليه في وحدة القسطره المخيه بمستشفى الحسين الجامعي .
الهدف من البحث: تقييم وعلاج التشوه الشرياني الوريدي الدماغي بعد العلاج التداخلي بالقسطره المخيه في عينة من المرضى المصريين .
المرضي وطرق العلاج: علاج جميع المرضى الذين يعانون من التشوه الشرياني الوريدي الدماغي في وحدة القسطره المخيه منذ ديسمبر 2006 حتى أبريل 2021 سواء حدث انفجار للتشوه او لم يحدث (سواء كان عرضيًا أو تم اكتشافه بالصدفة) مع وجود مخاطر نزيف عالية بسبب الحجم الصغير (أقل من 3 سم) ، والتصريف الوريدي العميق ، و / أو تمدد الأوعية الدموية المصاحب في مستشفيات جامعه.
نتائج البحث: وجدنا أن غالبية حالات التشوه الشرياني الوريدي الدماغي تظهر متوسط الاعمار الذين يعانون من التشوه (32) عامًا ووجدنا أيضًا ثمانية وعشرين مريضًا (16.6٪) لديهم تاريخ مرضي في العائله للتشوه الشرياني الوريدي الدماغي. و كان العرض الأكثر شيوعًا هو النزيف داخل الجمجمة ، وجاء الصرع في المرتبة الثانية ، وجاء الصداع في المرتبة الثالثة واعراض عصبيًه آخرا بسبب التشوه الشرياني الوريدي نفسه. و كشفت دراستنا أن موقع التشوه الشرياني الوريدي الدماغي في نصف الكرة الأيمن أكثر من نصف الكرة الأيسر.وكانت أهم الملاحظات في دراستنا هي الاختلاف المهم الواضح في قطر بؤره التشوه الشرياني الوريدي ، وتصنيف اسبيتزلر و مارتن للتشوه الشرياني الوريدي الدماغي بعد العلاج بالقسطره المخيه مقارنةً بما قبل العلاج بالقسطره المخيه. كما كشفت دراستنا أن إمداد الجافية كان سالبًا في غالبية المرضى. وكانت نتيجة دراستنا بعد 320 جلسة في 169 مريضًا هي الانسداد الوعائي الكامل ل20 مريضا ، والانخفاض الجزئي في قطر النيدوس في 129 مريضًا وتحويل 20 مريضا للجراحه الاشعاعيه .
الأستنتاج:إلى أن العلاج القسطره المخيه التداخليه للتشوه الشرياني الوريدي الدماغي آمن وفعال ويمكن أن يحقق معدلات عالية الغلق الكامل والشبه الكامل.
الكلمات الدالة: التشوهات الشريانة الوريدية المخية , بعد التدخل بالقسطره المخية ,التقييم الأكلينيكي و الأشعاعي